^West AR, Galloway MP (1997). "Inhibition of glutamate reuptake potentiates endogenous nitric oxide-facilitated dopamine efflux in the rat striatum: an in vivo microdialysis study". Neurosci. Lett. 230 (1): 21–4. doi:10.1016/S0304-3940(97)00465-5. PMID9259454. S2CID1425558.
^Pollack MH, Roy-Byrne PP, Van Ameringen M, Snyder H, Brown C, Ondrasik J, Rickels K (2005). "The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study". J Clin Psychiatry. 66 (11): 1401–8. doi:10.4088/JCP.v66n1109. PMID16420077.
^Alberati D, Moreau JL, Lengyel J, et al. (February 2012). "Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia". Neuropharmacology. 62 (2): 1152–61. doi:10.1016/j.neuropharm.2011.11.008. PMID22138164. S2CID12504169.
^Boissard CG, Gribkoff VK (1993). "The effects of the adenosine reuptake inhibitor soluflazine on synaptic potentials and population hypoxic depolarizations in area CA1 of rat hippocampus in vitro". Neuropharmacology. 32 (2): 149–55. doi:10.1016/0028-3908(93)90095-K. PMID8383814. S2CID10716297.
^Barker, Eric L.; Randy D. Blakely (1995). Norepinephrine and serotonin transporters: molecular targets of antidepressant drugs. In: Psychopharmacology: the fourth generation of progress.
^Ravna AW, Sylte I, Dahl SG (2003). "Molecular mechanism of citalopram and cocaine interactions with neurotransmitter transporters". J Pharmacol Exp Ther. 307 (1): 34–41. doi:10.1124/jpet.103.054593. PMID12944499. S2CID14035346.
^Apparsundaram S, Stockdale DJ, Henningsen RA, Milla ME, Martin RS (2008). "Antidepressants targeting the serotonin reuptake transporter act via a competitive mechanism". J Pharmacol Exp Ther. 327 (3): 982–990. doi:10.1124/jpet.108.142315. PMID18801947. S2CID15873647.
^Pechnick RN, Bresee CJ, Poland RE (2006). "The role of antagonism of NMDA receptor-mediated neurotransmission and inhibition of the dopamine reuptake in the neuroendocrine effects of phencyclidine". Life Sci. 78 (17): 2006–11. doi:10.1016/j.lfs.2005.09.018. PMID16288927.
^ abcRothman RB, Silverthorn ML, Baumann MH, Goodman CB, Cadet JL, Matecka D, Rice KC, Carroll FI, Wang JB, Uhl GR, et al. (1995). "Studies of the biogenic amine transporters. VI. Characterization of a novel cocaine binding site, identified with [125I]RTI-55, in membranes prepared from whole rat brain minus caudate". J Pharmacol Exp Ther. 274 (1): 385–395. PMID7616423.
^ abcRothman RB, Cadet JL, Akunne HC, Silverthorn ML, Baumann MH, Carroll FI, Rice KC, de Costa BR, Partilla JS, Wang JB, et al. (1994). "Studies of the biogenic amine transporters. IV. Demonstration of a multiplicity of binding sites in rat caudate membranes for the cocaine analog [125I]RTI-55". J Pharmacol Exp Ther. 270 (1): 296–309. PMID8035327.
^ abChen F, Larsen MB, Sánchez C, Wiborg O (2005). "The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors". Eur. Neuropsychopharmacol. 15 (2): 193–198. doi:10.1016/j.euroneuro.2004.08.008. PMID15695064. S2CID22917322.
^Müller WE, Singer A, Wonnemann M (2001). "Hyperforin – antidepressant activity by a novel mechanism of action". Pharmacopsychiatry. 34 (Suppl 1): S98–102. doi:10.1055/s-2001-15512. PMID11518085. S2CID21872392.
^ abChatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Müller WE (1998). "Hyperforin as a possible antidepressant component of hypericum extracts". Life Sci. 63 (6): 499–510. doi:10.1016/S0024-3205(98)00299-9. PMID9718074.
^Marsh WL, Davies JA (October 2002). "The involvement of sodium and calcium ions in the release of amino acid neurotransmitters from mouse cortical slices elicited by hyperforin". Life Sciences. 71 (22): 2645–55. doi:10.1016/S0024-3205(02)02104-5. PMID12354583.
^Buchholzer ML, Dvorak C, Chatterjee SS, Klein J (May 2002). "Dual modulation of striatal acetylcholine release by hyperforin, a constituent of St. John's wort". The Journal of Pharmacology and Experimental Therapeutics. 301 (2): 714–9. doi:10.1124/jpet.301.2.714. PMID11961077.